List of Tables:

Table 1: Summary of Food Allergy Epidemiology and Market (2025–2036)

Table 2: Upcoming Key Catalysts

Table 3: Key Conferences and Meetings

Table 4: Key Transactions and Collaborations

Table 5: News Flow

Table 6: Recommendations About the Diagnosis of IgE-mediated Food Allergy

Table 7: Recommendations About the Management of IgE-mediated Food Allergy

Table 8: Certainty of Evidence

Table 9: Addendum Guidelines for the Prevention of Peanut Allergy in the United States

Table 10: Recommendations Table of Global Allergy and Asthma European Network (GA2LEN) Guidelines

Table 11: Considerations for Implementing Guideline Recommendations

Table 12: A Summary of Prevention Measures for the Onset of Food Allergy

Table 13: Total Prevalent Cases of Food Allergy in the 7MM (in thousands) (2022–2036)

Table 14: Physician Diagnosed Prevalent Food Allergy Cases in 7MM (in thousands) (2022–2036)

Table 15: Food-Challenge-defined Food Allergy Cases in the 7MM (in thousands) (2022–2036)

Table 16: Physician-Diagnosed Prevalent Food Allergy Cases in the United States (in thousands) (2022–2036)

Table 17: Gender-specific Diagnosed Prevalent Cases of Food Allergy in the United States (in thousands) (2022–2036)

Table 18: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in the United States (in thousands) (2022–2036)

Table 19: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in the United States (in thousands) (2022–2036)

Table 20: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in the United States (in thousands) (2022–2036)

Table 21: Total Treated Cases of Food Allergy in the United States (in thousands) (2022–2036)

Table 22: Physician-Diagnosed Prevalent Food Allergy Cases in EU4 and the UK (in thousands) (2022–2036)

Table 23: Gender-specific Diagnosed Prevalent Cases of Food Allergy in Germany (in thousands) (2022–2036)

Table 24: Gender-specific Diagnosed Prevalent Cases of Food Allergy in France (in thousands) (2022–2036)

Table 25: Gender-specific Diagnosed Prevalent Cases of Food Allergy in Italy (in thousands) (2022–2036)

Table 26: Gender-specific Diagnosed Prevalent Cases of Food Allergy in Spain (in thousands) (2022–2036)

Table 27: Gender-specific Diagnosed Prevalent Cases of Food Allergy in the UK (in thousands) (2022–2036)

Table 28: Gender-specific Diagnosed Prevalent Cases of Food Allergy in EU4 and the UK (in thousands) (2022–2036)

Table 29: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in Germany (in thousands) (2022–2036)

Table 30: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in France (in thousands) (2022–2036)

Table 31: Allergen-specific DIgnosed Prevalent Cases of Food Allergy in Italy (in thousands) (2022–2036)

Table 32: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in Spain (in thousands) (2022–2036)

Table 33: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in the UK (in thousands) (2022–2036)

Table 34: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in EU4 and the UK (in thousands) (2022–2036)

Table 35: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in Germany (in thousands) (2022–2036)

Table 36: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in France (in thousands) (2022–2036)

Table 37: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in Italy (in thousands) (2022–2036)

Table 38: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in Spain (in thousands) (2022–2036)

Table 39: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in the UK (in thousands) (2022–2036)

Table 40: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in EU4 and the UK (in thousands) (2022–2036)

Table 41: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in Germany (in thousands) (2022–2036)

Table 42: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in France (in thousands) (2022–2036)

Table 43: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in Italy (in thousands) (2022–2036)

Table 44: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in Spain (in thousands) (2022–2036)

Table 45: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in the UK (in thousands) (2022–2036)

Table 46: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in EU4 and the UK (in thousands) (2022–2036)

Table 47: Total Treated Cases of Food Allergy in EU4 and the UK (in thousands) (2022–2036)

Table 48: Physician-Diagnosed Prevalent Food Allergy Cases in Japan (in thousands) (2022–2036)

Table 49: Gender-specific Diagnosed Prevalent Cases of Food Allergy in Japan (in thousands) (2022–2036)

Table 50: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in Japan (in thousands) (2022–2036)

Table 51: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in Japan (2022–2036)

Table 52: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in Japan (2022–2036)

Table 53: Total Treated Cases of Food Allergy in Japan (in thousands) (2022–2036)

Table 54: Competitive Landscape of Marketed Therapies

Table 55: Competitive Landscape of Emerging Therapies Under Development for Food Allergy

Table 56: Viaskin (DBV712 and DBV135) Peanut and Milk Patch, Clinical Trial Description, 2026

Table 57: Epinephrine Sublingual Film (Anaphylm) Clinical Trial Description, 2026

Table 58: Remibrutinib (RHAPSIDO/LOU064), Clinical Trial Description, 2026

Table 59: PVX108, Clinical Trial Description, 2026

Table 60: Ozureprubart (RPT904), Clinical Trial Description, 2026

Table 61: Sublingual Immunotherapy (SLIT)-Tablet, Clinical Trial Description, 2026

Table 62: STMC-103H, Clinical Trial Description, 2026

Table 63: VLP Peanut, Clinical Trial Description, 2026

Table 64: Linvoseltamab (LYNOZYFIC) + dupilumab (DUPIXENT), Clinical Trial Description, 2026

Table 65: INT301, Clinical Trial Description, 2026

Table 66: MY006, Clinical Trial Description, 2026

Table 67: Key Market Forecast Assumption of Food Allergy in the United States

Table 68: Key Market Forecast Assumption of Food Allergy in EU4 and the UK

Table 69: Key Market Forecast Assumption of Food Allergy in Japan

Table 70: Total Market Size of Food Allergy by Country in the 7MM, USD million (2022–2036)

Table 71: Total Market Size of Food Allergy by Therapies in the 7MM, USD million (2022–2036)

Table 72: Total Market Size of Food Allergy in the United States, USD million (2022–2036)

Table 73: Total Market Size of Food Allergy by Therapies in the United States, USD million (2022–2036)

Table 74: Total Market Size of Food Allergy in EU4 and the UK, USD million (2022–2036)

Table 75: Total Market Size of Food Allergy by Therapies in Germany, USD million (2022–2036)

Table 76: Total Market Size of Food Allergy by Therapies in France, USD million (2022–2036)

Table 77: Total Market Size of Food Allergy by Therapies in Italy, USD million (2022–2036)

Table 78: Total Market Size of Food Allergy by Therapies in Spain, USD million (2022–2036)

Table 79: Total Market Size of Food Allergy by Therapies in the UK, USD million (2022–2036)

Table 80: Total Market Size of Food Allergy by Therapies in EU4 and the UK, USD million (2022–2036)

Table 81: Total Market Size of Food Allergy in Japan, USD million (2022–2036)

Table 82: Total Market Size of Alport Syndrome by Therapies in Japan, USD million (2022–2036)

Table 83: The United States Reimbursement for Food Allergy Therapies

Table 84: Summary of Recommendations in EU4 and The UK

Table 85: IQWiG Assessment for Food Allergy

Table 86: HAS Decision on Food Allergy

Table 87: NHI Pricing for Food Allergy Therapies

List of Figures:

Figure 1: Allergic Disease Development

Figure 2: The Interplay Between Environmental Factors That may be Relevant for Food Allergy Development

Figure 3: Diagnosis Algorithm for Food Allergy

Figure 4: Total Prevalent Cases of Food Allergy in the 7MM (2022–2036)

Figure 5: Physician Diagnosed Prevalent Food Allergy Cases in 7MM (2022–2036)

Figure 6: Food-Challenge-defined Food Allergy Cases in the 7MM (2022–2036)

Figure 7: Physician-Diagnosed Prevalent Food Allergy Cases in the United States (2022–2036)

Figure 8: Gender-specific Diagnosed Prevalent Cases of Food Allergy in the United States (2022–2036)

Figure 9: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in the United States (2022–2036)

Figure 10: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in the United States (2022–2036)

Figure 11: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in the United States (2022–2036)

Figure 12: Total Treated Cases of Food Allergy in the United States (2022–2036)

Figure 13: Physician-Diagnosed Prevalent Food Allergy Cases in EU4 and the UK (2022–2036)

Figure 14: Gender-specific Diagnosed Prevalent Cases of Food Allergy in EU4 and the UK (2022–2036)

Figure 15: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in EU4 and the UK (2022–2036)

Figure 16: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in EU4 and the UK (2022–2036)

Figure 17: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in EU4 and the UK (2022–2036)

Figure 18: Total Treated Cases of Fod Allergy in EU4 and the UK (2022–2036)

Figure 19: Physician-Diagnosed Prevalent Food Allergy Cases in Japan (2022–2036)

Figure 20: Gender-specific Diagnosed Prevalent Cases of Food Allergy in Japan (2022–2036)

Figure 21: Allergen-specific Diagnosed Prevalent Cases of Food Allergy in Japan (2022–2036)

Figure 22: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Children) in Japan (2022–2036)

Figure 23: Severity-specific Diagnosed Prevalent Cases of Food Allergy (Adult) in Japan (2022–2036)

Figure 24: Total Treated Cases of Food Allergy in Japan (2022–2036)

Figure 25: Total Market Size of Food Allergy in the 7MM, in USD million (2022–2036)

Figure 26: Total Market Size of Food Allergy in the United States, in USD million (2022–2036)

Figure 27: Market Size of Food Allergy by Therapies in the United States, in USD million (2022–2036)

Figure 28: Total Market Size of Food Allergy in EU4 and the UK, in USD million (2022–2036)

Figure 29: Market Size of Food Allergy by Therapies in EU4 and the UK, in USD million (2022–2036)

Figure 30: Total Market Size of Food Allergy in Japan, in USD million (2022–2036)

Figure 31: Market Size of Food Allergy by Therapies in Japan, in USD million (2022–2036)

Figure 32: HTA

Figure 33: The 6MM HTA Bodies

Figure 34: The US Healthcare Programs

Figure 35: Reimbursement Process of Germany

Figure 36: Reimbursement Process of France

Figure 37: Reimbursement Process of Italy

Figure 38: Reimbursement Process in Spain

Figure 39: Reimbursement Process in the United Kingdom

Figure 40: UK MHRA Approval Through IRF

Figure 41: Reimbursement Process in Japan

Food Allergy Companies:

• DBV Technologies
• Roche
• Novartis
• Aravax
• ARS Pharmaceuticals
• ALK-Abelló
• Alfresa Pharma
• Stallergenes Greer
• Aquestive Therapeutics
• Novartis
• Aravax
• Siolta Therapeutics
• RAPT Therapeutics